Quantcast

Latest placebo Stories

2014-04-02 12:20:48

Commonly used neurological medication proves successful at blocking brain's reward system triggers Relapse is the most painful and expensive feature of drug addiction—even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after...

2014-03-31 08:29:05

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value...

2014-03-25 08:29:27

SAN DIEGO, March 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced top-line data from a proof of concept Phase 1/2 clinical trial evaluating the use of HTI-501 in the treatment of cellulite. The primary endpoint of the clinical trial was met, showing a statistically significant improvement in the appearance of cellulite in the areas of the patients' skin treated with HTI-501 as determined by physician assessment 28 days after treatment compared to...

2014-03-22 08:21:21

- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2) EAST HANOVER, N.J., March 22, 2014 /PRNewswire/ -- Novartis today announced results from the Phase III FEATURE and JUNCTURE studies showing secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response...

Multiple Sclerosis May Benefit From Statins
2014-03-19 10:09:06

Brett Smith for redOrbit.com - Your Universe Online At first, multiple sclerosis is recognized by sporadic neurological symptoms – a condition called relapsing-remitting MS. Within a decade or so, greater than 50 percent of patients acquire secondary progressive MS, a continuous deterioration of symptoms and boost in disability. Currently, there are no approved drugs for treating this later stage of the disease. However, a newly published study in the UK medical journal The Lancet has...

2014-03-13 17:18:53

Investigators call on drug regulators to provide clear evidence to patients on claims of drug side effects At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them. Almost all the side effects reported in these trials "occurred anyway when patients...

Are Your Pets Benefiting From Their Pain Medication?
2014-03-13 15:17:15

Tracey Peake, North Carolina State University How do you know that your pet is benefiting from its pain medication? A new clinical trial design could help overcome pet owners’ unconscious observation bias and determine whether the drugs they test are effective. When animals are recruited for clinical trials, particularly for pain medications, researchers must rely on owner observation to determine whether the medication is working. Sounds simple enough, but as it turns out, human and...

2014-03-03 08:31:20

6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO ARRY-502, an oral CRTh2 antagonist, was studied in a...

2014-02-26 08:27:36

More information at: http://thesynergytrial.org MILL VALLEY, Calif., Feb. 26, 2014 /PRNewswire/ -- K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related